Challenging Cases in CKD Anemia: The Kidneys and Heart as Linked Parts – An In The Clinic Activity




This educational activity is provided by Integrity Continuing Education, Inc.


This educational activity is supported by an educational grant from GlaxoSmithKline.


Anemia is a common disease sequela of chronic kidney disease (CKD) that can worsen and complicate the bidirectional disease continuum between CKD and cardiovascular disease. Anemia in CKD can be treated, which can extend the lives of patients with CKD, reduce hospitalizations, and improve quality of life. However, anemia in CKD is persistently undermanaged because current treatments are in and of themselves linked with increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance.

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.


Ajay K. Singh, MBBS, FRCP, MBA
Brigham and Women’s Hospital
Senior Associate Dean
Postgraduate Medical Education
Harvard Medical School
Boston, Massachusetts

Kirsten L. Johansen, MD
Chief of Nephrology
Hennepin Healthcare
Professor of Medicine
University of Minnesota
Minneapolis, Minnesota

Release date: October 14, 2022
Expiration date: October 14, 2023
Estimated time to complete activity: 60 minutes

This educational activity has been designed for nephrologists, endocrinologists, cardiologists, and internal medicine physicians involved in the management of patients with CKD.


Upon completion of this educational activity, participants should be able to:

  • Clarify the disease burden imposed by untreated or undertreated anemia in patients with CKD, including in racially diverse populations
  • Correlate the pathophysiology of anemia in CKD with viable therapeutic targets
  • Identify appropriate candidates for emerging CKD-related anemia treatments among patients on or not on dialysis based on efficacy and safety data from recent clinical trials

There are no fees for participating and receiving CME credit for this activity. During the period of October 14, 2022 through October 14, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ajay K. Singh, MBBS, FRCP, MBA
Chair, Editorial Board: Nephrology Times
Consultant: Bayer, GlaxoSmithKline, Zydus

Kirsten L. Johansen, MD
Advisory Boards: Akebia, GlaxoSmithKline, Vifor Pharma

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest